Drug Profile
Research programme: gastrointestinal disorder therapies - Takeda
Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Monash Institute of Pharmaceutical Sciences; Queen Mary University of London; Takeda
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal disorders
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for research development in Gastrointestinal-disorders in Japan
- 19 Feb 2015 Takeda and Queen Mary University of London agree to develop drugs in Japan country for Gastrointestinal disorders
- 09 Dec 2014 Early research in Gastrointestinal disorders in Japan (unspecified route)